Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | CTSG | P08311 | 1/20 | 0.37 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.37 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.37 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.37 |
| ▸ | EP300 | Q09472 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL531694 | 1.00 | LMNA (0.42) | LMNADDB1CRBNNPSR1TSHR | |
| SCHEMBL2369273 | 1.00 | LMNA (0.42) | LMNADDB1CRBNNPSR1TSHR | |
| SCHEMBL8926068 | 0.80 | CA2 (0.37) | LMNADDB1CRBNNPSR1TSHR | |
| SCHEMBL31403360 | 0.79 | HDAC8 (0.36) | DDB1CRBNTSHRHTTHDAC8 | |
| SCHEMBL5872462 | 0.79 | HDAC8 (0.36) | DDB1CRBNTSHRHTTHDAC8 | |
| SCHEMBL5872468 | 0.79 | HDAC8 (0.36) | DDB1CRBNTSHRHTTHDAC8 | |
| SCHEMBL13949518 | 0.78 | LMNA (0.38) | LMNADDB1CRBNNPSR1TP53 | |
| SCHEMBL11365386 | 0.74 | GBA1 (0.41) | LMNADDB1CRBNTSHRHTT | |
| SCHEMBL2366727 | 0.74 | CA2 (0.42) | LMNACA2 | |
| SCHEMBL1443388 | 0.74 | CA2 (0.42) | LMNACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5801249-A | Chiral auxiliaries | OXFORD ASYMMETRY INTERNATIONAL PLC (GB) | 1998-09-01 | — | — | US | claimed |
| WO-1995018112-A1 | IMPROVEMENTS IN OR RELATING TO CHIRAL AUXILIARIES | OXFORD ASYMMETRY LIMITED (GB) | 1995-07-06 | — | — | WO | claimed |
| WO-2024040267-A2 | DIRECT SYNTHESIS OF N-(3-SUBSTITUTED-CHROMAN-4-YL)-7H- PYRROLO[2,3-D]PYRIMIDIN-4-AMINES AND DERIVATIVES THEREOF | MITOKININ, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| WO-2023146785-A1 | PYRROLIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20160075724-A1 | CETP Inhibitors | MERCK SHARP & DOHME (US) | 2016-03-17 | — | — | US | disclosed |
| US-20140221383-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8735435-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-27 | — | — | US | disclosed |
| EP-1765793-B1 | ANACETRAPIB AND OTHER CETP INHIBITPRS | MERCK SHARP & DOHME (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2415759-A1 | CETP inhibitors | Merck Sharp & Dohme Corporation (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20100125075-A1 | Antibacterial Agents | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2010-05-20 | — | — | US | disclosed |
| US-20100099716-A1 | CETP INHIBITORS | MERCK SHARP & DOHME LLC | 2010-04-22 | — | — | US | disclosed |
| EP-1052984-A1 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-11-22 | — | — | EP | disclosed |
| WO-2000058294-A1 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-10-05 | — | — | WO | disclosed |
| WO-2000043001-A1 | ANTI-INFLAMMATORY AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-07-27 | — | — | WO | disclosed |
| WO-2000035440-A1 | N-FORMYL HYDROXYLAMINE DERIVATIVES AS ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-06-22 | — | — | WO | disclosed |
| WO-1999041232-A1 | CYTOSTATIC AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-08-19 | — | — | WO | disclosed |
| WO-1999039704-A1 | ANTIBACTERIAL AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-08-12 | — | — | WO | disclosed |
| US-5801249-A | Chiral auxiliaries | OXFORD ASYMMETRY INTERNATIONAL PLC (GB) | 1998-09-01 | — | — | US | disclosed |
| EP-0736017-A1 | IMPROVEMENTS IN OR RELATING TO CHIRAL AUXILIARIES | OXFORD ASYMMETRY LIMITED (GB) | 1996-10-09 | — | — | EP | disclosed |
| WO-1995018112-A1 | IMPROVEMENTS IN OR RELATING TO CHIRAL AUXILIARIES | OXFORD ASYMMETRY LIMITED (GB) | 1995-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221383-A1 | CETP INHIBITORS | CETP, APOB, MTTP | LMNA 449/4885DDB1 1074/4885CRBN 1600/4885 |
| US-20100125075-A1 | Antibacterial Agents | NQO2, DAO, Q6ZSR9 | LMNA 2435/4885DDB1 1738/4885CRBN 3601/4885 |
| US-20100099716-A1 | CETP INHIBITORS | CETP, APOB, MTTP | LMNA 449/4885DDB1 1074/4885CRBN 1600/4885 |
| US-20160075724-A1 | CETP Inhibitors | CETP, APOB, MTTP | LMNA 449/4885DDB1 1074/4885CRBN 1600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.